Background {#Sec1}
==========

Maintaining dose intensity is important for achieving the full benefits of chemotherapy in patients with potentially curable non-Hodgkin's lymphoma and breast cancer. In 1990, Epelbaum et al. reported a strong association between the relative dose intensity (RDI) of a standard CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) regimen and 5-year survival among 95 patients with diffuse large-cell lymphoma (DLCL) \[[@CR1]\]. The 5-year survival rate was 80 % in patients who received more than the median average RDI, whereas it was only 32 % in those who received less than the median average RDI (*P* \< 0.001). Similarly, analysis of the RDIs of three doxorubicin-based regimens (including CHOP) in 115 patients with DLCL revealed that RDI of doxorubicin greater than 75 % was the most important predictor of survival \[[@CR2]\]. A recently published retrospective analysis by Bosly et al. showed that survival of patients with diffuse large B-cell lymphoma (DLBCL) improved with an increasing average RDI (ARDI) of CHOP-21. Median survival was 7.08 years in those who received \>90 % of the ARDI, significantly longer than in those who received ≤90 % of the ARDI (*P* = 0.002) \[[@CR3]\]. In 1981, Bonadonna et al. reported a clear dose--response effect for CMF (cyclophosphamide, methotrexate, and 5-fluorouracil \[5-FU\]) chemotherapy in 449 women with breast cancer \[[@CR4]\]. Their results showed that patients receiving ≥85 % of the planned CMF dose had a 5-year relapse-free survival (RFS) rate of 77 %, compared with 48 % in patients receiving \<65 % of the planned dose. In 1995, 20-year follow-up data from the same group confirmed that RFS and overall survival (OS) were substantially better in patients who received ≥85 % of their planned dose than in those who received lower doses \[[@CR5]\].

In 1998, Budman et al. reported the results of a randomized trial of adjuvant CAF (cyclophosphamide, doxorubicin, 5-FU) for stage II breast cancer patients. In total, 1,550 breast cancer patients were randomly assigned to one of three treatment arms: high-, moderate-, or low-dose intensity treatments \[[@CR6]\]. The results revealed that the patients who received high- or moderate-dose intensity had significantly longer disease-free survival (*P* \< 0.001) and OS (*P* = 0.004) than those who received low-dose intensity.

Recently, some study protocols specify that patients who have an initial episode of febrile neutropenia (FN) should additionally receive granulocyte-colony stimulating factor (G-CSF) or prophylactic antibiotics in subsequent cycles, and dose modification of chemotherapy is unnecessary \[[@CR7]--[@CR9]\]. If there is a second FN episode despite G-CSF or antibiotic support, the protocols recommend a reduction in chemotherapy dose.

However, studies of patients with aggressive non-Hodgkin's lymphoma and early-stage breast cancer in the United States have reported that nearly half of such patients receive reduced dose-intensity chemotherapy \[[@CR10], [@CR11]\]. Additionally, how Japanese physicians manage outpatient chemotherapy and apply supportive measures to maintain RDI remains largely unknown. In Japan, chemotherapy for malignant lymphoma has been traditionally administered by hematologists, while chemotherapy for breast cancer is administered mainly by surgeons. This study was designed to clarify physicians' attitudes and practice patterns with respect to curative-intent chemotherapy and to define factors that negatively affect RDI maintenance in Japan.

Methods {#Sec2}
=======

We posted a questionnaire on a Japanese web site for physicians. Registration was required to access the questionnaire and those who completed the questionnaire could receive points from the web site as an incentive. The target respondents were physicians involved in the treatment of malignant lymphoma (Group ML) and those involved in the treatment of breast cancer (Group BC). Respondents in Group ML had to: 1) be a member of the Japanese Society of Hematology; 2) work at a hospital with more than 20 beds; 3) attend more than five patients with Non-Hodgkin's lymphoma who receive chemotherapy; and 4) attend at least one patient who received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) in the past year. Respondents in Group BC had to: 1) be a member of the Japanese Breast Cancer Society; and 2) attend more than 15 patients who received neoadjuvant or adjuvant chemotherapy in the past year. The number of current members of the Japanese Society of Hematology is around 6,400, whereas number of current members of the Japanese Breast Cancer Society is around 9,800, 68 % of which are surgeons.

In the questionnaire, we described a patient who received first-line chemotherapy for DLBCL in Group ML and a patient who received adjuvant chemotherapy for early breast cancer in Group BC. In the clinical scenarios, the patients suffer from low risk FN with The Multinational Association for Supportive Care in Cancer (MASCC) scores ≥21 \[[@CR12], [@CR13]\] and in Talcott group 4 \[[@CR14]\]. The questionnaire inquired about the management of FN and subsequent cycles of chemotherapy. The questions asked in the survey are listed in Table [1](#Tab1){ref-type="table"}. This survey was administered in Japanese. The surveillance period was from November 30 through December 11, 2012.Table 1Questions asked in the surveyQ. How old are you?1. ≤292. 30--343. 35--394. 40--445. 45--496. 50--547. 55--598. ≥60Q. In what decade did you receive your medical license?1. 2000s2. 1990s3. 1980s4. 1970sQ. Please select one of the following to indicate your area of specialty.(For Group ML)1. Board-certified internist2. Board-certified hematologist3. Board-certified oncologist4. Not applicable(For Group BC)1. Board-certified surgeon2. Board-certified breast surgeon3. Board-certified oncologist4. Board-certified internist5. Not applicableQ. Please select one of the following to indicate your place of employment.1. Academic medical center2. Cancer center or public hospital3. Private hospital4. OtherDiffuse large B-cell lymphoma (DLBCL)A 68-year-old woman was given a diagnosis of DLBCL, Stage IV A. There were hepatic metastases, but no bone marrow infiltration. She had no clinically significant past medical history. The International Prognostic Index was high-intermediate risk. Performance status (PS) was 0. Lactate dehydrogenase (LDH) was 1,250 IU/L. She was scheduled to receive six cycles of R-CHOP (rituximab 375 mg/m^2^ on day 1 or day 2, cyclophosphamide 750 mg/m^2^ on day 1, doxorubicin 50 mg/m^2^ on day 1, vincristine 1.4 mg/m^2^ on day 1 \[max 2 mg\], prednisone 100 mg on days 1--5) given every 21 days.Breast cancerA 68-year-old postmenopausal woman was given a diagnosis of right breast cancer, cT2N0M0 stage II A. She had no clinically significant past medical history. PS was 0. Right total mastectomy was performed. Pathological findings were as follows: pT 2.0 cm, grade 3, ly-, v-, pN1 (3/20), ER(-), PgR(-), HER2(-). She was scheduled to receive four cycles of TC (docetaxel 75 mg/m^2^ on day 1, cyclophosphamide 600 mg/m^2^ on day 1) given every 21 days.Q1. Would you manage low-risk febrile neutropenia in patients such as those describe above on an inpatient or outpatient basis?1. Outpatient2. InpatientQ2. (For those who chose outpatient management) Which of the following choices do you feel most closely describes the treatment you usually provide to this type of patient?1. Oral antibiotics only2. Oral antibiotics and G-CSF3. Observation4. OtherQ3. (For those who chose inpatient management) Which of the following choices do you feel most closely describes the treatment you usually provide to this type of patient?1. Intravenous antibiotics2. Intravenous antibiotics and G-CSF3. Other\[Clinical Course\]On the tenth day of the first cycle, she presented with a fever of 39 °C. A systematic review was unrevealing. Dietary and fluid intake was sufficient.Blood pressure, 135/80 mmHgHEENT: She had a clear oropharynx.Chest: No rales or wheezes were present.Cardiac: Normal S1 and S2. There was no murmur.Abdomen: Soft and flat. Bowel sounds were normal.Laboratory data: WBC:1,200/mm^3^, ANC:400/mm^3^, Hb:11.4 g/dL, PLT:158,000, GOT:23 IU/L, Alb:3.6 g/dL, BUN:18.8 mg/dL, Cr:0.6 mg/dL, CRP:1.8 mg/dLQ4. How do you modify the dose of subsequent courses of chemotherapy after febrile neutropenia? Please select one of the following options.1. Dose reduction is not required2. Dose reduction is required if febrile neutropenia was treated by intravenous antibiotics3. Dose reduction is required at any rate4. OtherQ5. How do you use antibiotics for the subsequent course of chemotherapy after febrile neutropenia? Please select one of the following options.1. Antimicrobial prophylaxis deserves consideration2. Antibiotics should be taken into account when the next episode of febrile neutropenia occurs3. I typically do not administer antibiotics4. OtherQ6. How do you use G-CSF for the subsequent course of chemotherapy after febrile neutropenia? Please select one of the following options.1. G-CSF prophylaxis deserves consideration2. G-CSF should be taken into account when neutropenia occurs3. G-CSF should be taken into account when the next episode of febrile neutropenia occurs4. I typically do not administer G-CSF5. OtherQ7. Regarding systems for managing adverse effects of outpatient chemotherapy, please check all appropriate responses.1. Emergency outpatient unit is open at all hours2. Clinical laboratory is open at all hours3. Diagnostic imaging unit is open at all hours4. Hospital antibiogram is available5. Health professionals provide patient and family education6. Chemotherapy telephone helpline is available7. Not applicable

All survey data were coded and analyzed with the use of standard EZR (Saitama Medical Center, Jichi Medical University), which is a graphical user interface for R (The R Foundation for Statistical Computing, version 2.13.0) \[[@CR15]\]. More precisely, it is a modified version of R commander (version 1.6--3) that includes statistical functions that are frequently used in biostatistics. For comparisons of categorical variables, Fisher's exact tests were used.

The execution of the survey followed the ethical principles outlined in the Declaration of Helsinki regarding human clinical research. The approval of the Ethics Committee of Nippon Medical School Musashikosugi Hospital was not required. This is because the regulation of the Ethics Committee of Nippon Medical School does not stipulate that a questionnaire survey for physicians requires ethical committee approval. Moreover, this is an anonymous questionnaire survey and we only use pseudonymized data.

Results {#Sec3}
=======

Table [2](#Tab2){ref-type="table"} lists the participant characteristics. Valid responses were obtained from 185 respondents in Group ML and 160 in Group BC; there were no invalid responses. In Group ML, 76 % (*n* = 141) of the respondents were board-certified hematologists, and 10 % (*n* = 18) were board-certified oncologists. In Group BC, 82 % (*n* = 131) were board-certified surgeons and 36 % (*n* = 58) were board-certified breast surgeons. Overall, 11 % (*n* = 17) of the respondents in Group BC were board-certified oncologists. In Group ML, 32 % (*n* = 59) of the respondents were working at academic medical centers, 32 % (*n* = 59) at cancer centers or public hospitals, and 36 % (*n* = 67) at private hospitals. In Group BC, 21 % (*n* = 33) were working at academic medical centers, 29 % (*n* = 46) at cancer centers or public hospitals, and 43 % (*n* = 69) at private hospitals.Table 2Demographic characteristics of respondentsCharacteristicGroup ML (*n* = 185)Group BC (*n* = 160)Number%Number%Age (years)≤2953≤291130--34221230--3412835--39301635--39332140--44372040--44311945--49432345--49392450--54281550--54231455--5913755--591610≥6074≥6053Decade of medical license2000s44242000s33211990s88481990s72451980s46251980s46291970s741970s96SpecialtyBoard-certified internist14277Board-certified surgeon13182Board-certified hematologist14176Board-certified breast surgeon5836Board-certified oncologist1810Board-certified oncologist1711Not applicable158Board-certified internist106Not applicable85Type of clinic/hospitalAcademic medical center5932Academic medical center3321Cancer center or public hospital5932Cancer center or public hospital4629Private hospital6736Private hospital6943Other00Other128

Table [3](#Tab3){ref-type="table"} summarizes how the respondents manage low-risk FN. 50 % (*n* = 93) of the physicians in Group ML chose outpatient treatment for FN as compared with 65 % (*n* = 104) in Group BC (*P* = 0.006). Among the respondents who chose outpatient treatment, a higher proportion of physicians chose both oral antibiotics and G-CSF in Group ML than in Group BC (82 % versus 53 %, *P* \< 0.001). However, intravenous antibiotics and G-CSF were preferred among physicians who chose inpatient treatment for FN.Table 3Management of low-risk febrile neutropeniaGroup MLGroup BC(*n* = 185)(*n* = 160)Number%Number%*P*-valueQ. Inpatient versus outpatient managementOutpatient935010465*P* = 0.006Inpatient92505635*P* = 0.006Total185100160100Q. (For those who chose outpatient management) Treatment of FNOral antibiotics only14154745*P* \< 0.001Oral antibiotics and G-CSF76825553*P* \< 0.001Observation0022*P* = 0.499Other3300*P* = 0.103Total93100104100Q. (For who choose inpatient management) Treatment of FNIntravenous antibiotics only91059*P* = 1Intravenous antibiotics and G-CSF83905191*P* = 1Other0000*P* = 1Total9210056100*Abbreviations*: *FN* febrile neutropenia

Table [4](#Tab4){ref-type="table"} summarizes how the respondents modify the dose of chemotherapy in patients who have FN and their attitudes toward the use of antibiotics and G-CSF for subsequent cycles of chemotherapy. In Group ML, 77 % (*n* = 143) of the physicians responded that "dose reduction is not required" compared with 31 % (*n* = 49) in Group BC (*P* \< 0.001). In Group BC, approximately one third of the physicians responded that "dose reduction is required if FN was treated by intravenous antibiotics" and another third responded that "dose reduction is required at any rate". Thirty-six percent (*n* = 67) of Group ML and 26 % (*n* = 42) of Group BC responded that "antimicrobial prophylaxis deserves consideration" (*P* = 0.049). Approximately half of the physicians in each group responded that "antibiotics are taken into account on the next episode of FN". Twenty-five percent (*n* = 47) of Group ML and 16 % (*n* = 26) of Group BC responded that "G-CSF prophylaxis deserves consideration" (*P* = 0.047). Approximately half of the physicians in each group responded that "G-CSF is taken into account when neutropenia occurs". About one third of Group BC responded that "G-CSF is taken into account when the next episode of FN occurs".Table 4Management of subsequent cycles of chemotherapy after low-risk FNGroup ML (*n* = 185)Group BC (*n* = 160)Number%Number%*P*-valueQ. Dose of chemotherapyDose reduction is not required143774931*P* \< 0.001Dose reduction is required if febrile neutropenia was treated by intravenous antibiotics18105635*P* \< 0.001Dose reduction is required at any rate22125534*P* \< 0.001Other2100*P* = 0.501Total185100160100Q. AntibioticsAntimicrobial prophylaxis deserves consideration67364226*P* = 0.049Antibiotics are taken into account on the next episode of febrile neutropenia91499559*P* = 0.065I typically don't administer antibiotics27152314*P* = 1Other0000*P* = 1Total185100160100Q. G-CSFG-CSF prophylaxis deserves consideration47252616*P* = 0.047G-CSF is taken into account when neutropenia occurs114627547*P* = 0.006G-CSF is taken into account on the next episode of febrile neutropenia1584629*P* \< 0.001I typically don't administer G-CSF74138*P* = 0.107Other2100*P* = 0.501Total185100160100

Table [5](#Tab5){ref-type="table"} shows the details of the systems used to manage adverse effects of outpatient chemotherapy. For this analysis, physicians who work at clinics with less than 12 beds were not included in Group ML, but were included in Group BC. Eight percent (*n* = 12) of physicians in Group BC worked at clinics with less than 20 beds. Eighty-six percent (*n* = 159) of Group ML and 70 % (*n* = 112) of Group BC responded that the "emergency outpatient unit is open at all hours". Sixty-nine percent (*n* = 128) of Group ML and 41 % (*n* = 66) of Group BC responded that the "clinical laboratory is open at all hours". Moreover, 63 % (*n* = 117) of Group ML and 33 % (*n* = 52) of Group BC responded that the "diagnostic imaging unit is open at all hours". Only 15 % (*n* = 27) of physicians in Group ML and 16 % (*n* = 26) of those in Group BC group responded that a "chemotherapy telephone helpline is available".Table 5System for managing adverse effects during outpatient chemotherapyGroup ML (*n* = 185)Group BC (*n* = 160)Number%Number%*P*-valueQ. Regarding the system for managing adverse effects of outpatient chemotherapy, please check all appropriate responsesEmergency outpatient unit is open at all hours1598611270*P* \< 0.001Clinical laboratory is open at all hours128696641*P* \< 0.001Diagnostic imaging unit is open at all hours117635233*P* \< 0.001Hospital antibiogram is available105574025*P* \< 0.001Health professions provide patient and family education81445233*P* = 0.035Chemotherapy telephone helpline is available27152616*P* = 0.765Not applicable00117*P* \< 0.001

Discussion {#Sec4}
==========

The most important finding of our study is that many Japanese physicians reduce the dose of chemotherapeutic agents after the first episode of low-risk FN in patients with potentially curable aggressive non-Hodgkin's lymphoma or early-stage breast cancer. In the questionnaire, we presented the case of a patient who had FN during treatment for aggressive non-Hodgkin's lymphoma or early-stage breast cancer in an outpatient setting (Table [1](#Tab1){ref-type="table"}). She was clinically stable without significant medical comorbidity on presentation. Her MASCC score \[[@CR12], [@CR13]\] was 24, and she was classified as Talcott's Group 4 \[[@CR14]\], indicating low-risk FN. As for the subsequent course of chemotherapy, a higher proportion of physicians in Group BC responded that "dose reduction is required at any rate" or that "dose reduction is required if FN was treated by intravenous antibiotics" than in Group ML.

As mentioned in the introduction, there is well-established evidence supporting the clinical significance of RDI and its impact on survival in patients with aggressive non-Hodgkin's lymphoma or early stage breast cancer \[[@CR1]--[@CR6]\]. This is why reducing the dose and delaying chemotherapy should be avoided. FN and severe prolonged neutropenia can lead to the decision to reduce chemotherapy dose and delay subsequent treatment cycles. In addition, the risk of fatal infection rises as the absolute neutrophil count falls below 500/mm^3^ and is higher in those with a prolonged neutropenia duration (\>7 days) \[[@CR16]\]. Therefore, management of afebrile and febrile neutropenia is significant. The Cochrane Haematological Malignancies Group published a review that compare the effectiveness of prophylactic administration of G-CSF or Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF) with antibiotics in cancer patients receiving chemotherapy \[[@CR17]\]. Two randomized controlled trials were eligible. This review showed non-significant results favoring antibiotics for preventing fever or hospitalization for FN compared with G-CSF. However, in one of the two trials, the chemotherapy dose intensity received by the antibiotic comparison group was much lower than in the GM-CSF group \[[@CR18]\], which may explain the increased incidence of infections in the GM-CSF group. A non-randomized comparison within a randomized controlled trial (GEPARTRIO study) lead to a different outcome \[[@CR19]\]. In breast cancer patients receiving TAC (docetaxel, doxorubicin and cyclophosphamide) pegfilgrastim alone or pegfilgrastim plus antibiotics provided suboptimal protection against FN and antibiotics alone was least effective.

Our results showed that that G-CSF and antibiotics are not commonly administered as prophylaxis against FN by Japanese physicians. G-CSF use for the management of established afebrile neutropenia was preferred in both groups. Guidelines recommend against the use of G-CSF in patients with afebrile neutropenia \[[@CR20]--[@CR23]\]. A randomized, double blind, placebo-controlled trial of G-CSF has been performed in afebrile outpatients with severe chemotherapy-induced neutropenia \[[@CR24]\]: G-CSF shortened the duration of neutropenia, but did not decrease the hospitalization rate for FN, length of hospital stay, the number of days of antibiotic therapy, and the likelihood of having a positive culture.

Guidelines support the use of G-CSF in patients with FN who are at high risk for infection-associated complications \[[@CR20]--[@CR23]\]. A randomized, open-label, non-placebo-controlled trial has evaluated the effectiveness of adding G-CSF to antibiotic therapy in patients with solid tumors and chemotherapy-induced high-risk FN \[[@CR25]\]. Adding G-CSF to antibiotic therapy was found to shorten the duration of neutropenia and reduce the duration of antibiotic therapy and hospitalization, but the treatment success rate, time to fever resolution, and mortality rate were similar in both treatment arms. Contrary to such evidence, many physicians use G-CSF with therapeutic intent.

In Japan, the majority of cancer care, including chemotherapy for solid tumors, has been historically performed by surgeons. Moreover, there is a shortage of medical oncologists in Japan. As of 2015, only 954 physicians have become Board-Certified Medical Oncologists of the Japanese Society of Medical Oncology (JSMO) \[[@CR26]\]. Oncology education and training system in Japan needs much improvement. In addition, pegfilgrastim was not available in Japan until November 2014, and hospital visits on successive days were required. These factors may have a negative impact on outpatient management of chemotherapy and supportive care.

The Japanese Breast Cancer Society has developed Clinical Practice Guidelines for the systemic treatment of breast cancer \[[@CR27]\]. These guidelines do not report how to use G-CSF or antibiotics as curative-intent chemotherapy. Including information about RDI and supportive measures into these guidelines may be an effective way to improve maintenance of dose-intensity.

About 50 % of Group ML and 35 % of Group BC chose to have the patient admitted to hospital for the treatment of FN. The American Society of Clinical Oncology (ASCO) clinical practice guidelines recommends outpatient management of low-risk FN as an option for carefully selected patients \[[@CR28]\]. Based on the ASCO's members' expert opinion, "access to a telephone and transportation 24 h a day" is one of the requirements for outpatient treatment. However, our survey revealed that support systems for outpatient chemotherapy have not been adequately established in many hospitals and clinics in Japan.

Our study has several important limitations. First, the respondents may have been forgetful or may have responded without understanding the full context of the situation presented in the survey. In addition, eligible respondents were limited to physicians who had access to the website, potentially introducing self-selection bias. Despite these limitations, we believe that our study represents an important step in the improvement of cancer chemotherapy in Japan.

Conclusions {#Sec5}
===========

In summary, our results suggest that supportive measures to deliver full dose-intensity chemotherapy are not widely used by Japanese physicians. Systems to support outpatient chemotherapy should thus be improved.
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